Anti-VCPIP1 monoclonal antibody
Pre-made anti-VCPIP1 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to VCPIP1/VCPIP1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IP2803-Ab-1/ GM-Tg-hg-IP2803-Ab-2 | Anti-Human VCPIP1 monoclonal antibody | Human |
| GM-Tg-rg-IP2803-Ab-1/ GM-Tg-rg-IP2803-Ab-2 | Anti-Rat VCPIP1 monoclonal antibody | Rat |
| GM-Tg-mg-IP2803-Ab-1/ GM-Tg-mg-IP2803-Ab-2 | Anti-Mouse VCPIP1 monoclonal antibody | Mouse |
| GM-Tg-cynog-IP2803-Ab-1/ GM-Tg-cynog-IP2803-Ab-2 | Anti-Cynomolgus/ Rhesus macaque VCPIP1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IP2803-Ab-1/ GM-Tg-felg-IP2803-Ab-2 | Anti-Feline VCPIP1 monoclonal antibody | Feline |
| GM-Tg-cang-IP2803-Ab-1/ GM-Tg-cang-IP2803-Ab-2 | Anti-Canine VCPIP1 monoclonal antibody | Canine |
| GM-Tg-bovg-IP2803-Ab-1/ GM-Tg-bovg-IP2803-Ab-2 | Anti-Bovine VCPIP1 monoclonal antibody | Bovine |
| GM-Tg-equg-IP2803-Ab-1/ GM-Tg-equg-IP2803-Ab-2 | Anti-Equine VCPIP1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-IP2803-Ab-1/ GM-Tg-hg-IP2803-Ab-2; GM-Tg-rg-IP2803-Ab-1/ GM-Tg-rg-IP2803-Ab-2; GM-Tg-mg-IP2803-Ab-1/ GM-Tg-mg-IP2803-Ab-2; GM-Tg-cynog-IP2803-Ab-1/ GM-Tg-cynog-IP2803-Ab-2; GM-Tg-felg-IP2803-Ab-1/ GM-Tg-felg-IP2803-Ab-2; GM-Tg-cang-IP2803-Ab-1/ GM-Tg-cang-IP2803-Ab-2; GM-Tg-bovg-IP2803-Ab-1/ GM-Tg-bovg-IP2803-Ab-2; GM-Tg-equg-IP2803-Ab-1/ GM-Tg-equg-IP2803-Ab-2 |
| Products Name | Anti-VCPIP1 monoclonal antibody |
| Format | mab |
| Target Name | VCPIP1 |
| Protein Sub-location | Introcelluar Protein |
| Category of antibody | |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
| Tag | Fc |
| Products description | Pre-made anti-VCPIP1 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-IP2803-Ag-1 | Recombinant multi-species VCIP1/ VCPIP1/ DUBA3 protein |
Target information
| Target ID | GM-IP2803 |
| Target Name | VCPIP1 |
| Gene ID | 80124,70675,286761,703582,486980,101089918,539643,100052090 |
| Gene Symbol and Synonyms | 4932442A08,5730421J18Rik,5730538E15Rik,DUBA3,mKIAA1850,VCIP135,VCPIP1 |
| Uniprot Accession | Q96JH7,Q8CF97 |
| Uniprot Entry Name | VCIP1_HUMAN,VCIP1_RAT |
| Protein Sub-location | Introcelluar Protein |
| Category | |
| Disease | N/A |
| Gene Ensembl | ENSG00000175073 |
| Target Classification | N/A |
The target: VCPIP1, gene name: VCPIP1, also named as DUBA3, VCIP135. Enables thiol-dependent deubiquitinase. Involved in protein deubiquitination; protein-DNA covalent cross-linking repair; and regulation of protein localization to chromatin. Located in cytoplasm and nucleus. [provided by Alliance of Genome Resources, Apr 2022].
About Gmab


GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.

